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Background: The aminoglycoside-resistance genes encoding aminoglycoside modifying enzymes and 16S rRNA
methyltransferases are main factors contributing to increasing resistance to aminoglycosides. Characterization and
distribution of antimicrobial resistance gene profiles provide important information on the potential difficulty of
treatment of bacteria. Several molecular methods have been developed to investigate the prevalence of
aminoglycoside-resistance genes. These existing methods are time-consuming, labor-intensive, expensive or limited
sensitivity in the epidemiological investigation. Therefore, it is necessary to develop a rapid, less-costly and high
throughput and sensitive method to investigate the distribution of antimicrobial resistance gene in clinical isolates.
Results: In this study, we developed a GeXP analyzer-based multiplex PCR assay to simultaneously detect seven
aminoglycoside-resistance genes, including aac(3)-II, aac(6′ )-Ib, aac(6′ )-II, ant(3′ ′ )-I, aph(3′ )-VI, armA and rmtB, and to
analyze the distribution of these genes in clinical Enterobacteriaceae isolates. Under optimized conditions, this assay
achieved a limit-of-detection as low as 10 copies of each of the seven genes. The presented method was applied
to analyze the distribution of aminoglycoside-resistance genes in 56 clinical Enterobacteriaceae isolates, and the
results were compared with that of the conventional single PCR assay. Kappa values of the two methods for
detecting each of the seven resistance genes were 0.831, 0.846, 0.810, 0.909, 0.887, 0.810 and 0.825, respectively.
Conclusion: This GeXP assay is demonstrated to be a rapid, cost-effective and high throughput method with high
sensitivity and specificity for simultaneously detecting seven common aminoglycoside-resistance genes.
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Aminoglycosides are potent bactericidal antibiotics tar-
geting the bacterial ribosome, where they bind to the
A-site and disrupt protein synthesis. They are particularly
active against aerobic, Gram-negative bacteria and act syn-
ergistically against certain Gram-positive organisms [1-3].
Unfortunately, their efficacy has been reduced by the surge* Correspondence: zhouxmphd@163.com; maxj@ivdc.chinacdc.cn
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reproduction in any medium, provided the orand dissemination of resistance. In some cases the levels
of resistance reached the point that rendered them virtu-
ally useless [4]. There are several considerable mecha-
nisms that cause resistance to aminoglycosides including:
1) the acquisition of modifying enzymes such as acetyl-
transferases, phosphotransferases and adenylyltransferases,
2) modification of the target by mutation in ribosomal
proteins [5] or in 16S rRNA [6], or by 16S rRNA
methyltransferase such as ArmA [7], Rmt families [8,9]
and NpmA [10], 3) decreased intracellular accumulation
of the antibiotic by alteration of outer membrane perme-
ability, diminished inner membrane transport, or active
efflux pump [11]. The main factors contributing to the
increasing isolates resistant to aminoglycosides were repor-
ted to be the widespread genes encoding aminoglycoside-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[2,12-14]. The most common aminoglycoside-modifying
enzyme gene types are aac(3)-II, followed by aac(6′)-I, ant
(3″)-I, aph(3′)-II, and ant(2″)-I in Escherichia coli [15]. Fur-
thermore, aac(6′)-II and aph(3′)-VI are respectively the sig-
nificant resistance determinants of gentamicin, tobramycin,
and amikacin in Pseudomonas aeruginosa [4,16]. In
addition, modification of 16S rRNA by methylases reduces
binding to aminoglycosides, leading to high-level resistance
to amikacin, kanamycin, tobramycin and gentamicin [17].
Currently, seven 16S rRNA methylase genes have been
identified (armA, rmtA, rmtB, rmtC, rmtD, rmtE, rmtF and
npmA), among which, armA and rmtB are the most com-
mon 16S rRNA methyltransferase genes [9,14,18,19].
Characterization and distribution of antimicrobial re-
sistance gene profiles provide important information on
the potential difficulty of treatment of bacteria. This in-
formation can be used to facilitate prompt and effective
treatment of bacterial infections. In order to investigate
the prevalence of aminoglycoside-resistance genes, sev-
eral methods have been developed, including conven-
tional single PCR and multiplex PCR assays combined
with agarose gel electrophoresis analysis, hybridization
with DNA probes, and sequence analysis [20,21]. Some
drawbacks with these existing methods are time-
consuming, labor-intensive, and difficult to analyze mul-
tiple genes simultaneously. DNA chips provide a versatile
platform for rapidly screening several thousand potential
antimicrobial resistance genes in parallel [22,23]. How-
ever, it is expensive and time-consuming for detecting
numerous clinical isolates in the epidemiological investi-
gation. So it is necessary to develop a rapid, cost effect-
ive and high throughput method to investigate the
distribution of aminoglycoside resistance gene in clinical
isolates.
The GenomeLab Gene eXpression Profiler genetic
analysis system (GeXP analyzer) provided by Beckman
Coulter Company (Brea, CA, USA) has been adopted by
our group and successfully applied in the rapid detec-
tion of pandemic influenza A H1N1 virus [24], simul-
taneous detection of 11 human papillomavirus (HPV)Table 1 Distribution of aminoglycoside resistance genes in 8
Strains No. Reference strains Presence of a
NF512663 Escherichia coli aac(6’)-Ib [aac
NF802568 Escherichia coli ant(3”)-II [aadA
NF811738 Klebsiella pneumoniae aac(6’)-Ib [aac
NF707346 Klebsiella pneumoniae ant(2”)-I [aadB
NF802824 Klebsiella pneumoniae acc(6’)-II
NF811834 Klebsiella pneumoniae aadA5
NF141160 Acinetobacter baumannii aac(3’)-I [aacC
NF910192 Pseudomonas putida aac(6’)-II & an
* Synonyms in the bracket.genotypes [25], sixteen human respiratory virus types/
subtypes [26] and nine serotypes of enteroviruses asso-
ciated with hand, foot, and mouth disease [27] with high
sensitivity and specificity. The general analysis proced-
ure of GeXP assay consists of chimeric primer-based
multiplex PCR amplification and capillary electrophor-
esis separation. In this study, a high throughput, cost-
effective GeXP analyzer-based multiplex PCR assay
(GeXP assay) was developed to simultaneously detect
seven aminoglycoside- resistance genes, including five
aminoglycoside-modifying enzymes genes [aac(3)-II,
aac(6′)-Ib, aac(6′)-II, ant(3″)-I and aph(3′)-VI] and two
16S rRNA methyltransferase genes [armA and rmtB],
and the results were compared with that of the conven-
tional single PCR assay.
Methods
Bacterial strains
In order to evaluate the efficacy of primers and PCR
assay, 8 reference strains listed in Table 1 (JN108884.1,
JN119854.1, JN108899.1, HQ880271.1, GU944731.1,
GU120473.1, JQ780837.1 and HQ880255.1) and 5 clin-
ical strains (Table 2, including 3 strains of Klebsiella
pneumoniae and 2 strains of Escherichia coli) were
selected as positive controls, Escherichia coli ATCC#
25922 and Escherichia coli J53 were used as negative
controls. In the initial experiment, the distributions of
aminoglycoside resistance genes among those controls
strains were confirmed by conventional PCR with the
specific primers listed in Table 3. Fifty six clinical iso-
lates of Enterobacteriaceae were used to evaluate the
utility of GeXP assay. All the clinical samples were
taken as part of standard patient care from the inpa-
tients at Guangzhou First Municipal People’s Hospital
from January 2008 to December 2009. This protocol
was approved by the Committee on the Use of Human
Subjects in Research at Guangzhou First Municipal
People’s Hospital, an affiliated hospital of Guangzhou
Medical College. All the informed consents from the in-
patients themselves or their guardians were obtained. In
initial experiments, the identification of the clinicalreference strains
minoglycoside resistance genes GenBank accession no.
A4]* JN108884.1
2] * JN119854.1
A4] *& ant(3”)-I [aadA1] * JN108899.1
] *& ant(3”)-I [aadA1] * HQ880271.1
GU944731.1
GU120473.1
1] * & ant(3”)-I [aadA1] * JQ780837.1
t(2”)-I [aadB] * HQ880255.1
Table 2 Distribution of aminoglycoside resistance genes in 5 positive control isolates
Strains
No. Species
Presence of aminoglycoside resistance genes
aac(3)-II aac(6’)-Ib aac(6’)-II ant(3”)-I aph(3’)-VI armA rmtB
1086 Klebsiella pneumoniae + + - + + + +
1135 Klebsiella pneumoniae + - + + + + +
1136 Klebsiella pneumoniae + + + + + + -
1174 Escherichia coli + + - + - + -
1313 Escherichia coli + + - + + + -
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(MICs) of antibiotics were confirmed by the VITEKW 2
system (bioMérieux, France) (Additional file 1). Forty
eight of the 56 isolates (including 30 strains of Klebsiella
pneumoniae and 18 strains of Escherichia coli) presen-
ted resistance to gentamicin (MIC≥16μg/mL), tobramy-
cin (MIC≥16μg/mL) and/or amikacin (MIC≥64μg/mL),
the other 8 isolates (including 5 strains of Klebsiella
pneumoniae and 3 strains of Escherichia coli) were sus-
ceptible to gentamicin (MIC≤4μg/mL), tobramycin
(MIC≤4μg/mL) and amikacin (MIC≤16μg/mL) according
to the standards of Clinical and Laboratory Standards
Institute (CLSI 2012).
Bacterial genomic DNAs extraction and mono-resistance
gene clone
The bacterial genomic DNA was extracted from overnight
cultures using MiniBEST Bacterial Genomic DNA Extrac-
tion Kit Ver.2.0 (TAKARA, Dalian, China). The entire cod-
ing regions of aac(3)-II, aac(6′)-Ib, aac(6′)-II, ant(3″)-I,
aph(3′)-VI, armA and rmtB were amplified individually
from the positive control isolates with the specific primer
listed in Table 3. PCR conditions for the amplifications























*The primers have been validated with referenced strains (GU944731.1 and HQ880230 s at 56°C and 1 min at 72°C and a final extension of
5 min at 72°C. PCR products were cloned using the
pMD18-T vector (TAKARA, Dalian, China), into E. coli
JM109 and positive clones were selected using an X-Gal
/IPTG LB agar plate containing ampicillin (100 mg/L).
Recombinant plasmids were purified with QIAGEN
Plasmid Mini Kit (Qiagen, Hilden, Germany), treated with
the RNAse to eliminate residual RNA and subjected to
DNA sequencing using T7 and SP6 sequence primers on
an AB SOLiDTM 4.0 System (Applied Biosystems, USA).
The obtained DNA sequences were compared with rele-






In this study, a total of one pair of universal primers (Tag-
F/Tag-R) and seven pairs of chimeric primers (specific
primers linked to the 3’ end to the universal primers) were
designed (Table 4). Tag-F (AGGTGACACTATAGAATA)
and Tag-R (GTACGACTCACTATAGGGA) were quasi-
T7 sequences and selected by default using the GeXPside-resistance genes









Table 4 Primers information of GeXP assay
Primer Sequence (5'→3')* GenBank accession no. Position Size (bp)
aac(3)-II
F:AGGTGACACTATAGAATAACTGTGATGGGATACGCGTC DQ449578.1 87359–87378 274
R:GTACGACTCACTATAGGGACTCCGTCAGCGTTTCAGCYA 87595–87576
aac(6’)-Ib
F:AGGTGACACTATAGAATACTGTTCAATGATCCCGAGGT JN861072.1 101468–101487 188
R:GTACGACTCACTATAGGGATGGCGTGTTTGAACCATGTA 101619–101600
aac(6’)-II
F:AGGTGACACTATAGAATATTCATGTCCGCGAGCACCCC GU944731.1 1307–1326 215
R:GTACGACTCACTATAGGGAGACTCTTCCGCCATCGCTCT 1485–1466
ant(3″)-I
F:AGGTGACACTATAGAATATGATTTGCTGGTTACGGTGAC HM106456.1 2207–2229 321
R:GTACGACTCACTATAGGGACGCTATGTTCTCTTGCTTTTG 2490–2470
aph(3’)-VI
F:AGGTGACACTATAGAATACGGAAACAGCGTTTTAGAGC JF949760.1 727–746 288
R:GTACGACTCACTATAGGGAGGTTTTGCATTGATCGCTTT 975–956
armA
F:AGGTGACACTATAGAATATGCATCAAATATGGGGGTCT FJ410928.1 3953–3972 247
R:GTACGACTCACTATAGGGATGAAGCCACAACCAAAATCT 4162–4143
rmtB





*Universal tag sequences are underlined.
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the primers for aac(3)-II, aac(6′)-II, ant(3″)-I were previ-
ously reported [15,20]. The gene-specific sequences of
other four pairs of primers were designed by NCBI
Primer-Blast and GeXP eXpress Profiler softwares. The
primer for aac(6′)-Ib also covered the variant gene aac
(6′)-Ib-cr which not only resulted in aminoglycosides re-
sistance but also mediated quinolone resistance [28]. The
5’ ends of the forward and reverse universal primers were
labeled with fluorescent dye Cy5 and purified with high
pressure liquid chromatography. All chimeric primers
were purified by polyacrylamide gel electrophoresis.Evaluation of the specificity of the GeXP assay
The DNA templates were extracted bacterial genomic
DNAs of the 8 reference strains, 5 positive control iso-
lates, 2 negative controls and 7 recombinant plasmids
harboring each of the 7 resistance genes, respectively.
The mono GeXP assay and GeXP assay were developed
using single template and each pair of gene-specific
primers (for mono GeXP assay) or using single template
in a multiplex primer format (for GeXP assay), respect-
ively, to ascertain the actual amplicon size of each target
region. The PCR assays were performed with QIAGEN
Multiplex PCR kit (Qiagen, Hilden, Germany) in a 25 μl
volume containing 12.5 μl of 2× QIAGEN Multiplex
PCR Master Mix (HotStarTaqW DNA Polymerase, Multi-
plex PCR Buffer, dNTP Mix) and 1 μl of DNA templates.
The mono GeXP assay contained 50 nM of each pair ofgene-specific chimeric primers individually while the
GeXP assay contained 50 nM of each of 7 pairs of gene-
specific chimeric primers and 500 nM of the universal
Tag primers as the final concentrations, nuclease-free
water was added to 25 μl reaction volume. The PCR was
performed under the following conditions: 95°C for 10
min, followed by three steps of amplification procedures
reaction according to the temperature switch PCR (TSP)
strategy [29]: step 1, 10 cycles of 95°C for 30 s, 55°C for
30 s, and 72°C for 30 s; step 2, 10 cycles of 95°C for 30
s, 65°C for 30 s, and 72°C for 30 s; step 3, 20 cycles of
95°C for 30 s, 48°C for 30 s, and 72°C for 30 s (Figure 1).Separation by capillary electrophoresis (CE) and fragment
analysis
PCR products were combined with DNA Size Standard at
the volume ratio of 2: 0.25 per reaction in 25 μl of Sample
Loading Solution and separated on a GeXP Analyzer by ca-
pillary electrophoresis, following the protocols as described
previously [27,30]. After amplified fragments were sepa-
rated, the peaks were initially analyzed using the Frag-
ment Analysis module of the GeXP system software and
matched to the appropriate amplified products. The peaks
height for each gene was reported in the electropherogram,
respectively (Figure 1). The dye signal strength was mea-
sured by fluorescence spectrophotometry in arbitrary units
(A.U.) of optical fluorescence. For all amplified products,
the reaction was considered positive when the value of dye
signal was over 1000 A.U. In addition, PCR products were
Figure 1 Diagram of the analysis procedure of GeXP assay. The analysis procedure of GeXP assay consists of chimeric primer-based multiplex
PCR amplification and capillary electrophoresis separation. The principle of GeXP multiplex amplification assay is based on the amplification of
two sets of primers: the gene-specific chimeric primers and the dye-labeled universal primers. After amplified fragments were separated, the
peaks of genes were analyzed and reported on the electropherogram, respectively.
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Evaluation of the limit of detection of the GeXP assay
The limit of detection of GeXP assay was measured by
using 7 purified recombinant plasmids containing seven
complete resistance genes, respectively. The concentration
for each resistance gene was quantitated by spectrophotom-
etry (NanoDrop ND-2000) and serial ten-fold diluted from
104 copies to 1 copy per microliter, and then individually
subjected to the GeXP assay. The concentrations of specific
primers were then optimized according to the amplification
efficiency of the GeXP assay using single template. The sen-
sitivity of the optimized GeXP assay for simultaneous
detection of seven genes was re-evaluated using pre-mixed
recombinant plasmids containing seven resistance genes
ranging from 104 copies to 1 copies for each resistance gene
per microliter for three times on three different days.
Application to clinical isolates
Genomic DNAs extracted from 56 clinical isolates were
used to illustrate the clinical performance of the optimized
GeXP assay. All the clinical isolates were detected in paral-
lel by conventional single PCR with the specific primers
reported by the previous study [13,31-35]. The amplifiedproducts were analyzed by electrophoresis at 100 V for
25 to 30 minutes in a 2% agarose gel stained with SYBR
green. Positive PCR products were purified, sequenced
using T7 and SP6 sequence primers on AB SOLiDTM
4.0 System (Applied Biosystems, USA) and compared with
the sequences in GenBank for gene type identification by
using the BLAST algorithm.
Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Sciences (SPSS) software (version
13.0) for Windows. The x2-test and Fisher’s exact test
were conducted to measure the detection agreement of
GeXP assay with conventional single PCR method.
Results and discussion
In this study, we adopted seven pairs of chimeric gene-
specific primers to develop a GeXP assay for simultaneous
detection of seven common aminoglycoside-resistance
genes including five aminoglycoside-modifying enzymes
genes [aac(3)-II, aac(6′)-Ib, aac(6′)-II, ant(3″)-I and aph
(3′)-VI] and two 16S rRNA methyltransferase genes
[armA and rmtB].
The principle of proposed GeXP assay is based on
the amplification with two sets of primers: the uni-
versal primers and the gene-specific chimeric primers
(gene-specific primers linked to the 3’ ends of universal
primer sequences). During the first few cycles of PCR,
Figure 2 The specificity of GeXP assay for the detection of aac(3)-II, aac(6′)-Ib, aac(6′)-II, ant(3″)-I, aph(3′)-VI, armA and rmtB. Seven
recombinant plasmids harboring aminoglycoside-resistance genes were respectively detected via the GeXP assay. All the specific peaks were
observed presenting the gene-specific target amplicons of aac(3)-II, aac(6′ )-Ib, aac(6′ )-II, ant(3′ ′ )-I, aph(3′ )-VI, armA and rmtB, respectively (a~g). The
negative control assay clearly showed the DNA size standard from 140 to 420 nt (peaks in red color) without nonspecific products presented (h).
Figure 3 The sensitivity of GeXP assay for detection of seven aminoglycoside-resistance genes. The GeXP assay was carried out using
different concentrations of seven premixed recombinant plasmids with 1000 copies (a), 100 copies (b), 10 copies (c) and 5 copies (d),
respectively. All of seven aminoglycoside-resistance genes could be detected at 1000, 100 and 10 copies levels (a, b and c); only aac(6′ )-II (217 bp)
and ant(3′ ′ )-I (321 bp) could be detected at 5 copies levels in the optimized GeXP assay (d).
Hu et al. BMC Microbiology 2013, 13:58 Page 6 of 9
http://www.biomedcentral.com/1471-2180/13/58
Table 5 Comparison of GeXP assay and conventional






Conventional single PCR Measures of
agreement
Positive Negative Total Kappa values*
aac(3)-II
Positive 37 2 39
0.831 (P=0.000)Negative 2 15 17
Total 39 17 56
aac(6')-Ib
Positive 11 3 14
0.846 (P=0.000)Negative 0 42 42
Total 11 45 56
aac(6')-II
Positive 8 2 10
0.810 (P=0.000)Negative 1 45 46
Total 9 47 56
ant(3″)-I
Positive 40 2 42
0.909 (P=0.000)Negative 0 14 14
Total 40 16 56
aph(3')-VI
Positive 10 0 10
0.887 (P=0.000)Negative 2 44 46
Total 12 44 56
armA
Positive 40 2 42
0.810 (P=0.000)Negative 2 12 14
Total 42 14 56
rmtB
Positive 14 3 17
0.825 (P=0.000)Negative 1 38 39
Total 15 41 56
*As a rule of thumb, values of Kappa from 0.40 to 0.59 are considered
moderate, 0.60 to 0.79 substantial, and 0.80 outstanding.
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verse primers. In later stages of PCR, amplification is pre-
dominantly carried out by universal forward and reverse
primers. All gene targets in the multiplex panel are ampli-
fied by the correspondent chimeric primers and the
universal primers. The universal primer is fluorescently
dye-labeled enabling subsequent fluorescence detection of
amplicons by capillary electrophoresis. The temperature
switch PCR (TSP) strategy was adopted to optimize the
amplification parameters. The triphasic PCR parameters
of the TSP allow a multiplex PCR to be performed under
standardized PCR conditions, and therefore do not require
optimization of each individual PCR assay. The optimal
settings for three different denaturation temperatures and
the amplification cycle conditions were determined in the
current protocol. The concentration of the fluorescently
dye-labeled universal primers was almost ten times that of
the chimeric primers in the GeXP assay, so in the last
20 cycles of PCR, amplification was carried out predomin-
antly with universal forward and reverse tag primers
(Figure 1). This should reduce the occurrence ofpreferential amplification in the reaction and minimize
nonspecific reactions.
Evaluation of the specificity of the GeXP assay
In mono GeXP assay, each pair of gene-specific primers
could amplify the target region of the corresponding
aminolycoside resistance gene without nonspecific prod-
ucts. The amplicon size for each target resistance gene
was as follows, aac(3)-II: 267-269 bp, aac(6′)-Ib: 189-
191 bp, aac(6′)-II: 217-218 bp, ant(3″)-I: 320-322 bp,
aph(3′)-VI: 286-288 bp, armA: 248-249 bp and rmtB:
174-177 bp. In GeXP assay using seven recombinant
plasmids as templates, all the specific amplification
peaks were observed presenting the gene-specific target
amplicon without cross-amplification (Figure 2). In
GeXP assay using 8 reference strains and 5 positive
control strains as templates, all the correspondent genes
in this study could be detected without nonspecific amp-
lification. The other aminoglycoside resistance genes
(e.g., ant(2”)-I and aadA5) which were not targeted in
this study did not generate nonspecific amplification in the
GeXP assay. All the amplicons of mono GeXP assay were
sequenced and confirmed as the target genes by BLAST
comparison with relevant sequences in the GenBank data-
base (data not shown).
Evaluation of the analytic sensitivity of the GeXP assay
The sensitivity of the GeXP assay was measured using
quantitative recombinant plasmids. The GeXP assay
with 50 nM of each pair of gene-specific chimeric
primers could individually detect as few as 5 copies of
armA, 10 copies of aac(3)-I, aac(6′)-Ib and rmtB, about
100 copies of aac(6′)-II, aph(3′)-VI and ant(3″)-I per
reaction. Based on all the amplification efficiency (above
analytic sensitivity results) of GeXP assay with single
recombinant plasmid template, the concentration of
each chimeric primer in the optimized GeXP assay was
adjusted as follows: the primers concentrations of aac
(3)-II, aac(6′)-Ib, armA and rmtB were 50 nM, while the
concentrations of the other three pairs of chimeric
primers [including aac(6′)-II, aph(3′)-VI and ant(3″)-I]
were doubled up to 100 nM. The optimized GeXP assay
reduced the potential interference due to the preferred
amplification in mixed settings and achieved a sensitiv-
ity of 10 copies when seven pre-mixed recombinant
plasmids templates were present in three independent
experiments on three different days (Figure 3).
Application to clinical specimens and statistical analysis
Fifty six strains of Enterobacteriaceae were detected sim-
ultaneously by both the GeXP assay and the conventional
single PCR followed by electrophoresis analysis in a 2%
agarose gel. The distribution of aminoglycoside resistance
genes detected by GeXP assay in 56 clinical isolates was
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both assays were confirmed as true target genes by
comparing with relevant sequences in the GenBank data-
base (data not shown). All of the 48 resistant isolates (30
strains of Klebsiella pneumoniae and 18 strains of
Escherichia coli) harbored at least one modifying enzyme
gene and one or two 16S rRNA methylase genes. None of
the 8 susceptible isolates harbored these resistance genes
by both assays. In comparison with the results of conven-
tional single PCR, the sensitivities of the GeXP assay for
detection of aac(3)-II, aac(6′)-Ib, aac(6′)-II, ant(3″)-I, aph
(3′)-VI, armA and rmtB were 92.50% (37/40), 100%
(11/11), 88.89% (8/9), 100% (40/40), 83.33% (10/12),
95.24% (40/42) and 93.33% (14/15),respectively, and the
specificities were 88.23% (15/17), 93.33% (42/45), 95.74%
(45/47), 87.50% (14/16), 100% (44/44), 85.71% (12/14) and
92.68% (38/41), respectively. The Kappa values of the
GeXP assay and conventional single PCR for detecting the
seven resistance genes were 0.831, 0.846, 0.810, 0.909,
0.887, 0.810 and 0.825, respectively. Those specimens that
were negative by the conventional single PCR but positive
by the GeXP assay (Table 5) were confirmed later by
mono-GeXP assay and sequenced to be true positives,
suggesting the optimized GeXP assay performed a better
sensitivity than the conventional method. Meanwhile,
some genes were detected as positive by conventional
method but negative by multiplex GeXP assay (4th column
of Table 5). The false negative genes of multiplex GeXP
assay could be detected by mono-GeXP assay with
less than 2000 A. U. dye signal strength of the peaks in
these false negatives. The later analysis of the distribution
of seven aminoglycoside-resistance genes showed that all
of false negatives of multiplex GeXP assay harbored more
than four genes, and the concentration of each gene
in these isolates largely varied, suggesting the false nega-
tives of multiplex GeXP assay were missed due to the
ignorance of the lower peak (less than 2000 A. U. dye
signal strength) overcast by higher peaks (more than
100000 A. U.).
The GeXP assay in our study can simultaneously
detect 7 genes related to resistance to aminoglycosides.
The cost is about 5£ per test, versus 5£ using commer-
cial real-time PCR kit for individual gene in a single
PCR assay. The whole reaction was completed in one
tube within 2 hours, followed by capillary electrophor-
esis separation on the GeXP analyzer in 45 min, so the
total turn around time (TAT) is less than 3 hours, versus
12-24 hours by antibiotic susceptibility test (AST). This
strategy of multiplex PCR amplification would be used
to detect more resistance genes with high sensitivity and
specificity. In addition, two 96-well plates can be placed
in parallel in a GeXP machine at the same time, which
can be combined with the automation workstation to
further increase the throughput of the samples.Conclusions
The GeXP assay is a time-saving, cost-effective and high
throughput method with high sensitivity and speci-
ficity for simultaneously detecting seven common
aminoglycoside-resistance genes. Further improvement
by large-scale studies for determination of the sensitiv-
ity, specificity, and clinical utility of this new method
will be needed before GeXP assay can be implemen-
ted effectively in routine testing environments for
molecular epidemiologic survey of resistance genes
and offer a directory suggestion for clinical antibiotic
therapy.
Additional file
Additional file 1: Minimal inhibitory concentration of antimicrobials
and distribution of aminoglycoside resistance genes in 56 clinical
isolates.
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